Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2008

View Archived Issues

Bisphosphonate-antibiotic combination compounds prevent osteomyelitis in vivo

Tremelimumab evaluated in melanoma and gastric and esophageal cancer patients

CYT-21304, a multifunctional nanotherapy improves tumor targeting of paclitaxel

FDA approves Biovail's NDA for Aplenzin once-daily for depression in adults

Shire acquires global rights to Metazym for metachromatic leukodystrophy from Zymenex

INCB-028060, a novel c-Met kinase inhibitor demonstrates benefits in cancer therapy

Palomid-529: A novel antiangiogenic, antitumor agent from Paloma Pharmaceuticals

Novel agents for arthritis and other inflammatory/autoimmune disorders revealed in recent patents

Wyeth withdraws application for extension to European marketing authorization for Tygacil

Arana and Kyowa Hakko sign agreement to codevelop ART-104 for colorectal cancer

Epix reports positive results from reread of images from phase III studies of Vasovist

Addex initiates phase I trial of two formulations of ADX-10059 for GERD

FDA grants permission to Stem Cell Therapeutics to initiate its phase IIb trial of NTx-265

Cara initiates phase I clinical trial for novel long-acting analgesic, CR-845

European Commission approves HIV protease inhibitor Aptivus

Swissmedic grants orphan drug status for CUV-1647 for erythropoietic porphyries

Acusphere submits NDA to FDA for the Imagify ultrasound imaging agent

New therapeutic options for HCV infection disclosed in recent GSK and Tibotec patents

E.U. approves Zevalin as first-line consolidation treatment

Recent Bayer patent divulges new compounds for renal disorders

Arrowhead subsidiaries Calando and Insert Therapeutics complete merger

Dyax and Cubist enter license agreement for development and commercialization of DX-88

Novartis applies for Japanese approval of vildagliptin in type 2 diabetes

FDA approves once-a-month dose of Actonel for postmenopausal osteoporosis

Astellas Pharma and CoMentis sign collaboration agreement for beta-secretase inhibitors

Nventa reports results from fourth cohort in phase I clinical trial of Hsp-E7 in CIN

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...